行情

CRIS

CRIS

居里
NASDAQ

实时行情|Nasdaq Last Sale

1.530
-0.050
-3.16%
已收盘, 18:50 12/12 EST
开盘
1.570
昨收
1.580
最高
1.630
最低
1.490
成交量
22.61万
成交额
--
52周最高
2.900
52周最低
0.6200
市值
5,080.04万
市盈率(TTM)
-1.7212
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

CRIS 新闻

  • 来自诺贝尔奖官网的八卦:爱因斯坦是锦鲤,村上不算是陪跑王
  • 澎湃新闻.2天前
  • Kinase inhibitors in focus after Merck bid for ArQule
  • seekingalpha.3天前
  • The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling
  • Benzinga.5天前
  • Curis up 8% premarket on encouraging CA-4948 in NHL
  • seekingalpha.6天前

更多

所属板块

生物技术和医学研究
+0.57%
制药与医学研究
+0.73%

热门股票

名称
价格
涨跌幅

CRIS 简况

Curis, Inc. is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company's drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target programmed death ligand-1 (PDL1) and V-domain Ig suppressor of T-cell activation (VISTA) immune checkpoint proteins, both of which independently function as negative regulators of immune activation. CA-4948 is an oral small molecule drug candidate that is designed to inhibit the Interleukin-1 receptor-associated kinase 4 (IRAK4) kinase, which is a transducer of toll-like receptor or certain interleukin receptor signaling pathways.
展开

Webull提供Curis, Inc.的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。